Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants

Chen, Chien‐Hung; Yang, Pei–Ming; Huang, Guan‐Tarn; Lee, Hsuan-Shu; Sung, Juei‐Low; Sheu, Jin‐Chuan

doi:10.1016/s0929-6646(09)60231-x

Cited by 251 publications

(229 citation statements)

References 19 publications

Supporting

Mentioning

207

Contrasting

Order By: Relevance

“…In Taiwan, HBV and HCV are endemic and are acquired via different modes of transmission. Most patients with CHB tend to acquire the infection early in life, usually perinatally, whereas many patients with CHC acquire the infection as young adults [10,11]. The comparison of the safety data from the clinical practice of Peg-IFN-based therapy in CHB and CHC provides a unique opportunity to investigate the effects of this treatment in a Taiwanese patient population with two distinct but related diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan

et al. 2010

View full text Add to dashboard Cite

Purpose Pegylated interferon (Peg-IFN)-based therapy is effective in treating chronic hepatitis B (CHB) and C (CHC) but frequently induces adverse events (AEs). This study was conducted to compare the incidence of Peg-IFNbased therapy-associated AEs in Taiwanese patients with CHB and CHC. Methods Fifty-six patients with CHB and 103 age-, sexand treatment duration-matched patients with CHC were enrolled. Patients with CHB were treated with Peg-IFN-a2a 180 lg/week for 24 weeks (HBeAg ? , n = 31) or 48 weeks (HBeAg -, n = 25); patients with CHC were treated with Peg-IFN-a-2a 180 lg/week plus ribavirin 1,000-1,200 mg/day for 24 weeks (genotype 2/3, n = 57) or 48 weeks (genotype 1, n = 46).Results Significantly higher incidences of Peg-IFN-related AEs, especially neuropsychiatric symptoms, and ribavirin-associated skin manifestations were observed in patients with CHC compared with those with CHB, with either the 24-or 48-week regimen. Frequencies of laboratory abnormalities, except for anemia, were comparable in both groups. Neither group showed overt hepatic decompensation. Frequency of dose reduction was similar between the groups. Substantially higher rates of early termination and severe AEs were observed in patients with CHC. Conclusions Patients with CHB treated with Peg-IFN had fewer AEs than patients with CHC treated with Peg-IFN/ ribavirin. All patients were treated safely.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In Taiwan, HBV and HCV infections are endemic and are the most important agents of chronic liver disease [10,11]. Whether the intensity and frequency of AEs are similar between Taiwanese patients with CHB and CHC who receive Peg-IFN-based therapy remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Taiwan is a hyper-endemic region for liver diseases such as cirrhosis and hepatocellular carcinoma (HCC), and infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are primary etiologic factors [1,2]. Before the launch of the universal childhood HBV vaccination policy in 1984, the prevalence rate of HBV infection in Taiwan was 15% to 20% [3].…”

Section: Introductionmentioning

confidence: 99%

“…Further, mortality due to fulminant hepatic failure and HCC also dramatically decreased following implementation of the vaccination program [7]. In a large-scale Taiwanese survey undertaken for evaluating HBV and HCV seroprevalence, increased HBsAg and anti-HCV seroprevalence rates (17.3% and 4.4%, respectively) were observed due to the inclusion of subjects born prior to the vaccination era [2]. Recent results from a literature review evaluating the burden of HCV in Asia confirmed HCV infection rates of 1.8% to 5.5% in Taiwan [8].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B and C in Taiwanese patients with Schizophrenia: A Nationwide, Population-based study on prevalence, and healthcare utilization

Wang

Tang²,

Tsai

et al. 2017

J Psychol Psychiatry

View full text Add to dashboard Cite

Introduction: Hepatic viral infections (hepatitis B virus (HBV) and hepatitis C virus (HCV)) are endemic in Taiwan, and can progress to liver cirrhosis and hepatocellular carcinoma. Schizophrenia patients present substantial undiagnosed and untreated comorbidities compared with the general population. Hence, the prevalence of comorbid HBV/HCV infections in, and healthcare utilization by patients with schizophrenia should be determined.

show abstract

“…Taiwan is an area hyper-endemic for chronic HBV/ HCV infection and HCC (Tsai et al, 2001(Tsai et al, , 2004IARC, 2004;Chen et al, 2007;Kee and Lu, 2011). Persistent hepatic inflammation is a hallmark of habitual BQ chewing (Sarma et al, 1992;Lin et al, 2008;Angadi and Rao, 2011) and/or chronic HBV/HCV infection (Bouchard and Navas-Martin, 2011;El-Serag, 2012).…”

Section: Introductionmentioning

confidence: 99%

Impact of Chronic Hepatitis B and Hepatitis C on Adverse Hepatic Fibrosis in Hepatocellular Carcinoma Related to Betel Quid Chewing

Jeng

Tsai²,

Tsai³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The pathogenesis of hepatocellular carcinoma (HCC) related to habitual betel quid (BQ) chewing is unclear. Risk of HCCis increased with adverse hepatic fibrosis. This study aimed to assess the impact of chronic viral hepatitis on adverse hepatic fibrosis in HCC related to BQ chewing. This hospital-based case-control study enrolled 200 pairs of age-and gender-matched patients with HCC and unrelated healthy controls. Serologic hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus (anti-HCV), α-fetoprotein (AFP), and surrogate markers for significant hepatic fibrosis were measured. Information on substance-use habits was obtained with a questionnaire. By analysis of surrogate markers for hepatic fibrosis, the prevalence of significant hepatic fibrosis in patients chewing BQ was between 45.8% and 91.7%, whereas that for patients without BQ chewing was between 18.4% and 57.9%. The difference was significant (P <0.05 for each surrogate marker). Multivariate analysis indicated that cirrhosis with Child-Pugh C (odds ratio (OR) = 3.28; 95% confidence interval (CI), 1.29-8.37), thrombocytopenia (OR = 3.92, 95% CI, 1.77-8.68), AFP >400 mg/L (OR = 2.21, 95% CI, 1.05-4.66) and male gender (OR = 4.06, 95% CI, 1.29-12.77) were independent factors associated with habitual BQ chewing. In conclusion, adverse hepatic fibrosis and severe liver damage play important roles in the pathogenesis of BQrelated HCC, which could be aggravated by chronic hepatitis B and hepatitis C. BQ-cessation programs and prevention of chronic HBV/HCV infection are needed to prevent HCC related to BQ chewing.

show abstract

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants

Cited by 251 publications

References 19 publications

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan

Hepatitis B and C in Taiwanese patients with Schizophrenia: A Nationwide, Population-based study on prevalence, and healthcare utilization

Impact of Chronic Hepatitis B and Hepatitis C on Adverse Hepatic Fibrosis in Hepatocellular Carcinoma Related to Betel Quid Chewing

Contact Info

Product

Resources

About